Personalis, Inc. (PSNL)

Over the past six months, Personalis, Inc.'s stock price increased by 105.67% from April 8, 2025, to April 7, 2026, but decreased by 24.4% year-to-date as of April 11, 2026. Key events include the Q3 and Q4 2025 earnings calls, Medicare coverage decisions for breast and lung cancer surveillance, the appointment of Dr. Richard Chen as President, new publications advancing neoadjuvant treatment monitoring in breast cancer with NeXT Personal®, participation in conferences, and Oracle Investment Management disclosing a new stake in PSNL.

Personalis, Inc. has acknowledged variability and seasonality in its revenue, particularly in relation to clinical test volumes and the timing of reimbursement coverage. The company's guidance for 2026 assumes clinical revenue from Medicare reimbursement for breast and lung cancer surveillance, indicating that the timing and expansion of such coverage can influence demand and revenue recognition. The company's strategy involves accelerating clinical volume adoption ahead of full reimbursement coverage to establish market share, which can impact gross margins.

Personalis, Inc. is a genomics company focused on transforming cancer management through advanced personalized testing, operating in the Healthcare sector, primarily within the Drug Discovery and Biotechnology industries. The company provides genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. Personalis's business model includes providing large-scale sequencing services for population health initiatives, notably as the sole sequencing provider to the U.S. Department of Veterans Affairs Million Veteran Program (VA MVP). Its major products and services include NeXT Personal®, ImmunoID NeXT®, NeXT Dx® and NeXT Personal Dx®, ACE platform, and Pharma research solutions.

Personalis, Inc. is headquartered in Fremont, California, United States. The principal markets for the company's tests and services are in the United States and Europe.

In the past year, Personalis has experienced positive developments that have enhanced its brand reputation. These include securing Medicare coverage for its MRD test in breast cancer, which is a significant clinical proof point for its platform. The company has also been recognized among the "10 best diagnostics and research stocks to buy" by analysts. New publications advancing neoadjuvant treatment monitoring in breast cancer with NeXT Personal® further contribute to its scientific credibility and reputation.

Personalis, Inc. has a mixed ownership structure, with institutional investors holding a significant portion, approximately 42% to 70.78% of the company's stock. The general public holds about 17% of the shares, and insiders own approximately 13.04% of the stock. Major institutional owners include Merck & Co., Inc., T. Rowe Price Investment Management, Inc., and Lightspeed Management Company, L.L.C., among others.